相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Co-targeting of the PI3K pathway improves the response of BRCA1 deficient breast cancer cells to PARP1 inhibition
Siker Kimbung et al.
CANCER LETTERS (2012)
Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer
Harry D. Bear et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer
Gunter von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
High Throughput Molecular Analyses to Select Patients for Targeted Agents
M. Arnedos et al.
EUROPEAN JOURNAL OF CANCER (2011)
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Brian D. Lehmann et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Biology-Driven Phase II Trials: What Is the Optimal Model for Molecular Selection?
Fabrice Andre et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC).
J. O'Shaughnessy et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation
Felipe C. Geyer et al.
MODERN PATHOLOGY (2011)
Implications of personalized medicine-perspective from a cancer center
Thomas Tursz et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer.
Joyce O'Shaughnessy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Molecular Stratification of Triple-Negative Breast Cancers
Charles M. Perou
ONCOLOGIST (2011)
Treatment of HER2-overexpressing breast cancer
J. Baselga
ANNALS OF ONCOLOGY (2010)
Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study
Jens Huober et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer
Edith A. Perez et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
A Double-Blind, Randomized, Placebo-Controlled, Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib (SOR) in Combination with Paclitaxel (PAC) as a First-Line Therapy in Patients (pts) with Locally Recurrent or Metastatic Breast Cancer (BC).
W. Gradishar et al.
CANCER RESEARCH (2010)
RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab In Combination with Chemotherapy for Second-Line Treatment of HER2-Negative Metastatic Breast Cancer.
A. Brufsky et al.
CANCER RESEARCH (2010)
SOLTI-0701: A Multinational Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo When Administered in Combination with Capecitabine in Patients with Locally Advanced or Metastatic Breast Cancer (BC).
J. Baselga et al.
CANCER RESEARCH (2010)
Phase III Randomized Trial of Sunitinib (SU) vs. Capecitabine (C) in Patients (Pts) with Previously Treated HER2-Negative Advanced Breast Cancer (ABC).
C. Barrios et al.
CANCER RESEARCH (2010)
Comparison of Subgroup Analyses of PFS from Three Phase III Studies of Bevacizumab in Combination with Chemotherapy in Patients with HER2-Negative Metastatic Breast Cancer (MBC).
J. O'Shaughnessy et al.
CANCER RESEARCH (2010)
FinXX Final 5-Year Analysis: Results of the Randomised, Open-Label, Phase III Trial in Medium-to-High Risk Early Breast Cancer
H. Joensuu et al.
CANCER RESEARCH (2010)
First Efficacy Results of a Randomized, Open-Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without Capecitabine, in High-Risk Early Breast Cancer
J. O'Shaughnessy et al.
CANCER RESEARCH (2010)
Heterogeneity for Stem Cell-Related Markers According to Tumor Subtype and Histologic Stage in Breast Cancer
So Yeon Park et al.
CLINICAL CANCER RESEARCH (2010)
Treating triple-negative breast cancer by a combination of rapamycin and cyclophosphamide: An in vivo bioluminescence imaging study
Qing Zeng et al.
EUROPEAN JOURNAL OF CANCER (2010)
Androgen receptor expression in breast cancer patients tested for BRCA1 and BRCA2 mutations
Gunda Pristauz et al.
HISTOPATHOLOGY (2010)
Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
Daniel P. Silver et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer.
S. J. Isakoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Safety and efficacy of the oral PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for the first- or second-line treatment of patients with metastatic triple-negative breast cancer: Results from the safety cohort of a phase I/II multicenter trial.
R. A. Dent et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A phase II trial of trabectedin (T) in patients (pts) with HER2-positive and BRCA1/2 germ-line-mutated metastatic breast cancer (MBC)
K. L. Tedesco et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer
K. A. Gelmon et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer
David W. Miles et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate
Alison H. M. Reid et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Pathologic Complete Response Rates in Young Women With BRCA1-Positive Breast Cancers After Neoadjuvant Chemotherapy
Tomasz Byrski et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Adenoid cystic carcinomas of the breast and salivary glands (or 'The strange case of Dr Jekyll and Mr Hyde' of exocrine gland carcinomas)
Caterina Marchio et al.
JOURNAL OF CLINICAL PATHOLOGY (2010)
Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation
Leo A. Niemeier et al.
MODERN PATHOLOGY (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Andrew Tutt et al.
LANCET (2010)
Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer.
Miguel Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets
N. Turner et al.
ONCOGENE (2010)
Cyclophosphamide Dose Intensification May Circumvent Anthracycline Resistance of p53 Mutant Breast Cancers
Jacqueline Lehmann-Che et al.
ONCOLOGIST (2010)
Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer
B. K. Linderholm et al.
ANNALS OF ONCOLOGY (2009)
Pattern of metastatic spread in triple-negative breast cancer
Rebecca Dent et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Invasive ductal carcinoma of the breast with the triple-negative phenotype: prognostic implications of EGFR immunoreactivity
Giuseppe Viale et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
mTOR Is a Promising Therapeutic Target Both in Cisplatin-Sensitive and Cisplatin-Resistant Clear Cell Carcinoma of the Ovary
Seiji Mabuchi et al.
CLINICAL CANCER RESEARCH (2009)
Recent Advances in Cancer Therapy Targeting Proteins Involved in DNA Double-Strand Break Repair
Emma Bolderson et al.
CLINICAL CANCER RESEARCH (2009)
Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization Array
Fabrice Andre et al.
CLINICAL CANCER RESEARCH (2009)
Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial
Judith Hugh et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Secretory breast carcinomas with ETV6-NTRK3 fusion gene belong to the basal-like carcinoma spectrum
Marick Lae et al.
MODERN PATHOLOGY (2009)
Triple-negative/basal-like breast cancer: review
Emad A. Rakha et al.
PATHOLOGY (2009)
Platinum-based chemotherapy in triple-negative breast cancer
B. Sirohi et al.
ANNALS OF ONCOLOGY (2008)
Sites of Distant Recurrence and Clinical Outcomes in Patients With Metastatic Triple-negative Breast Cancer High Incidence of Central Nervous System Metastases
Nancy U. Lin et al.
CANCER (2008)
Therapeutic Strategies for Triple-Negative Breast Cancer
Antoinette R. Tan et al.
CANCER JOURNAL (2008)
Basal-like breast cancer defined by five biomarkers has superior prognostic value then triple-negative phenotype
Maggie C. U. Cheang et al.
CLINICAL CANCER RESEARCH (2008)
DNA damage detection and repair pathways - Recent advances with inhibitors of checkpoint kinases in cancer therapy
Susan Ashwell et al.
CLINICAL CANCER RESEARCH (2008)
Keeping checkpoint kinases in line: new selective inhibitors in clinical trials
Susan Ashwell et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2008)
The combination of high cyclin E and Skp2 expression in breast cancer is associated with a poor prognosis and the basal phenotype
David Voduc et al.
HUMAN PATHOLOGY (2008)
A phase IB study evaluating BSI-201 in combination with chemotherapy in subjects with advanced solid tumors
J. J. Mahany et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumors
S. Kopetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane
Harold J. Burstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
Cornelia Liedtke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
HER2 status and efficacy of adjuvant anthracyclines in early breast cancer:: A pooled analysis of randomized trials
Alessandra Gennari et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies
Sonya D. Zabludoff et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients
David S. P. Tan et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells
Berengere Marty et al.
BREAST CANCER RESEARCH (2008)
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Kathy Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/triple-negative'' breast cancer cell lines growing in vitro
Richard S. Finn et al.
BREAST CANCER RESEARCH AND TREATMENT (2007)
HER2 and response to paclitaxel in node-positive breast cancer
Daniel F. Hayes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Triple-negative breast cancer: Clinical features and patterns of recurrence
Rebecca Dent et al.
CLINICAL CANCER RESEARCH (2007)
AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway
Ling-Zhi Liu et al.
CANCER RESEARCH (2007)
HER-2/neu status and response to CMF:: retrospective study in a series of operable breast cancer treated with primary CMF chemotherapy
Catalina Falo et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2007)
Descriptive analysis of estrogen receptor (ER)negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype - A population-based study from the California Cancer Registry
Katrina R. Bauer et al.
CANCER (2007)
The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes
Lisa A. Carey et al.
CLINICAL CANCER RESEARCH (2007)
Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo
David J. Matthews et al.
CELL CYCLE (2007)
Prognostic markers in triple-negative breast cancer
Emad A. Rakha et al.
CANCER (2007)
Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients:: The FNCLCC PACS 01 trial
Henri Roche et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen
A. S. Doane et al.
ONCOGENE (2006)
Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells
Stephen Hiscox et al.
BREAST CANCER RESEARCH AND TREATMENT (2006)
The role of capecitabine in first-line treatment for patients with metastatic breast cancer
Karen Gelmon et al.
ONCOLOGIST (2006)
KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcome
S Azoulay et al.
MODERN PATHOLOGY (2005)
Breast cancer molecular subtypes respond differently to preoperative chemotherapy
R Rouzier et al.
CLINICAL CANCER RESEARCH (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation
I Beuvink et al.
CELL (2005)
Expression profiling of purified normal human luminal and myoepithelial breast cells: Identification of novel prognostic markers for breast cancer
C Jones et al.
CANCER RESEARCH (2004)
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma
TO Nielsen et al.
CLINICAL CANCER RESEARCH (2004)
Hallmarks of 'BRCAness' in sporadic cancers
N Turner et al.
NATURE REVIEWS CANCER (2004)
Molecular portraits of human breast tumours
CM Perou et al.
NATURE (2000)
分享论文
